Status:
TERMINATED
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia
Lead Sponsor:
Yale University
Collaborating Sponsors:
Celgene Corporation
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
This study will determine whether or not Lenalidomide improves effectiveness of treatment for chronic lymphocytic leukemia following chemotherapy with two drugs commonly used to treat the disease (ben...
Eligibility Criteria
Inclusion
- Previous induction treatment with bendamustine and rituximab
- 18 or more years of age
- chronic lymphocytic leukemia
- ECOG performance status less than or equal to 2
- Absolute neutrophile count more than 1,000
- Platelet count more than 70,000
Exclusion
- Serious medical condition that would prevent treatment with lenalidomide
- Evidence of tumor lysis syndrome
- Any prior treatment with lenalidomide
Key Trial Info
Start Date :
March 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT01465230
Start Date
March 1 2012
End Date
November 1 2013
Last Update
October 23 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale Cancer Center
New Haven, Connecticut, United States, 06519